Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

Anktiva is combined with BCG, or Bacillus Calmette-Guérin, an immunotherapy drug delivered to the bladder through a catheter.

Soon-Shiong said nearly 1,000 patients have been treated successfully with Anktiva, many after standard treatments failed. He ...

A new bladder cancer treatment called TAR-200 has shown impressive results in a recent clinical trial. The study found that 82% of patients with high-risk non-muscle-invasive bladder cancer had their ...

Relmada Therapeutics is advancing NDV-01, a novel intravesical therapy for NMIBC, into phase 3 clinical trials, with Max ...

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...

NewsNation’s Chris Cuomo will host an hour-long special program, “Killing Cancer,” to examine a potentially groundbreaking ...

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...